Precipio | 10-Q: FY2025 Q3 Revenue: USD 6.767 M

Revenue: As of FY2025 Q3, the actual value is USD 6.767 M.

EPS: As of FY2025 Q3, the actual value is USD -0.05.

EBIT: As of FY2025 Q3, the actual value is USD -52 K.

Service Revenue, Net: $6.164 million for the three months ended September 30, 2025, compared to $4.599 million for the same period in 2024. For the nine months ended September 30, 2025, service revenue was $15.426 million, compared to $11.329 million in 2024.
Product Revenue: $721 thousand for the three months ended September 30, 2025, compared to $681 thousand in 2024. For the nine months ended September 30, 2025, product revenue was $1.999 million, compared to $1.936 million in 2024.

Net Loss: $79 thousand for the three months ended September 30, 2025, compared to $626 thousand in 2024. For the nine months ended September 30, 2025, net loss was $889 thousand, compared to $3.925 million in 2024.
Gross Profit: $3.005 million for the three months ended September 30, 2025, compared to $2.277 million in 2024. For the nine months ended September 30, 2025, gross profit was $7.574 million, compared to $4.913 million in 2024.
Operating Loss: $61 thousand for the three months ended September 30, 2025, compared to $597 thousand in 2024. For the nine months ended September 30, 2025, operating loss was $1.744 million, compared to $3.880 million in 2024.

Net Cash Provided by Operating Activities: $319 thousand for the nine months ended September 30, 2025, compared to net cash used in operating activities of $126 thousand in 2024.
Net Cash Used in Investing Activities: $251 thousand for the nine months ended September 30, 2025, compared to $179 thousand in 2024.
Net Cash Provided by Financing Activities: $848 thousand for the nine months ended September 30, 2025, compared to net cash used in financing activities of $144 thousand in 2024.

Allowance for Credit Losses: Adjustments for credit losses were $118 thousand for the three months ended September 30, 2025, compared to $71 thousand in 2024. For the nine months ended September 30, 2025, adjustments were $75 thousand, compared to $183 thousand in 2024.

Core Business Focus: The company aims to address cancer misdiagnoses by developing diagnostic products and services, leveraging its CLIA laboratories for R&D and product testing. The strategy includes expanding its product offerings and improving diagnostic accuracy to reduce healthcare costs.
Non-Core Business: The company is exploring additional revenue streams through partnerships with global healthcare distributors and expanding its market reach with innovative diagnostic solutions.
Priority: The company is focused on achieving its business plan, generating additional revenue, and securing financing to meet its obligations, despite substantial doubt about its ability to continue as a going concern.